ArticleFrontiers in chemistry2026
Novel 1,4-Diazepane derivatives as amyloid-beta (Aβ) aggregation inhibitors.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is characterized by the aggregation of amyloid-beta (Aβ) peptides, particularly Aβ42 and Aβ40, which contribute to neurotoxicity and disease progression. The development of novel small molecule inhibitors capable of preventing Aβ aggregation represents a promising therapeutic strategy. We report the design, synthesis and evaluation of a novel class of 1,4-diazepanes as anti-amyloid agents. Methods: A novel series of (1,4-diazepan-1-yl) (phenyl)methanone derivatives ( Results: Among the synthesized derivatives, compound Conclusion: These findings identify the 1,4-diazepane ring as a novel structural scaffold for the development of anti-amyloid agents. The dual inhibition of Aβ42 and Aβ40 aggregation, combined with neuroprotective and antioxidant effects, highlights compounds
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.